Cambrex Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St futures kick off September under pressure as yields, oil prices rise
- Oil up around 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
Cambrex Corp. (CBM) Tops Q4 EPS by 7c, Revenues Miss; Offers FY19 EPS Guidance
February 13, 2019 6:45 AM ESTCambrex Corp. (NYSE: CBM) reported Q4 EPS of $1.44, $0.07 better than the analyst estimate of $1.37. Revenue for the quarter came in at $212.3 million versus the consensus estimate of $214.76 million.
Announced the acquisition of Avista Pharma Solutions (Avista), an early clinical phase Contract Development, Manufacturing and Testing Organization, for approximately $252 million in total cash consideration. This transaction closed on January 2, 2019.Net revenue was $134.3 million under current U.S. GAAP, ASC 606 (ASC 606). Under ASC 605, the previous revenue recognition standard, and the only standard under which fourth quarter 2017 results were reported, Net revenue increased 16%... More